105 related articles for article (PubMed ID: 10381754)
1. Inhibition of phosphodiesterase III with milrinone increases renin secretion in human subjects.
Chiu YJ; Hu SH; Reid IA
J Pharmacol Exp Ther; 1999 Jul; 290(1):16-9. PubMed ID: 10381754
[TBL] [Abstract][Full Text] [Related]
2. cGMP stimulates renin secretion in vivo by inhibiting phosphodiesterase-3.
Beierwaltes WH
Am J Physiol Renal Physiol; 2006 Jun; 290(6):F1376-81. PubMed ID: 16449359
[TBL] [Abstract][Full Text] [Related]
3. Role of cyclic GMP-inhibitable phosphodiesterase and nitric oxide in the beta adrenoceptor control of renin secretion.
Chiu T; Reid IA
J Pharmacol Exp Ther; 1996 Aug; 278(2):793-9. PubMed ID: 8768733
[TBL] [Abstract][Full Text] [Related]
4. Stimulation of renin secretion by the phosphodiesterase IV inhibitor rolipram.
Chiu N; Park I; Reid IA
J Pharmacol Exp Ther; 1996 Mar; 276(3):1073-7. PubMed ID: 8786537
[TBL] [Abstract][Full Text] [Related]
5. Pharmacologic and pharmacodynamic effects of the selective low Km cyclic AMP phosphodiesterase III inhibitors WIN 63291 and WIN 62582.
Pagani ED; Dundore RL; Bode DC; Bacon ER; Singh B; Lesher GY; Buchholz RA; Silver PJ
J Cardiovasc Pharmacol; 1994 Sep; 24(3):403-10. PubMed ID: 7528296
[TBL] [Abstract][Full Text] [Related]
6. Dynamic changes of post-ischemic hepatic microcirculation improved by a pre-treatment of phosphodiesterase-3 inhibitor, milrinone.
Kume M; Banafsche R; Yamamoto Y; Yamaoka Y; Nobiling R; Gebhard MM; Klar E
J Surg Res; 2006 Dec; 136(2):209-18. PubMed ID: 17045613
[TBL] [Abstract][Full Text] [Related]
7. Phosphodiesterase III inhibition affects platelet-monocyte aggregate formation depending on the axis of stimulation.
Horn NA; Anastase DM; Hecker KE; Baumert JH; Scheffer GJ; Rossaint R
J Cardiothorac Vasc Anesth; 2006 Apr; 20(2):162-6. PubMed ID: 16616654
[TBL] [Abstract][Full Text] [Related]
8. Differential effects of specific phosphodiesterase isoenzyme inhibitors on bovine oocyte meiotic maturation.
Thomas RE; Armstrong DT; Gilchrist RB
Dev Biol; 2002 Apr; 244(2):215-25. PubMed ID: 11944932
[TBL] [Abstract][Full Text] [Related]
9. Analysis of the effects of phosphodiesterase type 3 and 4 inhibitors in cerebral arteries.
Birk S; Edvinsson L; Olesen J; Kruuse C
Eur J Pharmacol; 2004 Apr; 489(1-2):93-100. PubMed ID: 15063160
[TBL] [Abstract][Full Text] [Related]
10. Potentiation of erectile response and cAMP accumulation by combination of prostaglandin E1 and rolipram, a selective inhibitor of the type 4 phosphodiesterase (PDE 4).
Bivalacqua TJ; Champion HC; Rajasekaran M; Sikka SC; Kadowitz PJ; Doherty PC; Hellstrom WJ
J Urol; 1999 Nov; 162(5):1848-55. PubMed ID: 10524946
[TBL] [Abstract][Full Text] [Related]
11. Chronic type IV phosphodiesterase inhibition protects glomerular filtration rate and renal and mesenteric blood flow in a zymosan-induced model of multiple organ dysfunction syndrome treated with norepinephrine.
Thomas NJ; Carcillo JA; Herzer WA; Mi Z; Jackson EK
J Pharmacol Exp Ther; 2001 Jan; 296(1):168-74. PubMed ID: 11123377
[TBL] [Abstract][Full Text] [Related]
12. Differential regulation of human platelet responses by cGMP inhibited and stimulated cAMP phosphodiesterases.
Manns JM; Brenna KJ; Colman RW; Sheth SB
Thromb Haemost; 2002 May; 87(5):873-9. PubMed ID: 12038792
[TBL] [Abstract][Full Text] [Related]
13. Effect of sildenafil on renin secretion in human subjects.
Chiu YJ; Reid IA
Exp Biol Med (Maywood); 2002 Sep; 227(8):620-5. PubMed ID: 12192104
[TBL] [Abstract][Full Text] [Related]
14. Acute hemodynamic effects of intravenous sildenafil citrate in congestive heart failure: comparison of phosphodiesterase type-3 and -5 inhibition.
Botha P; Parry G; Dark JH; Macgowan GA
J Heart Lung Transplant; 2009 Jul; 28(7):676-82. PubMed ID: 19560695
[TBL] [Abstract][Full Text] [Related]
15. In vivo effects of phosphodiesterase III inhibitors on glucose metabolism and insulin sensitivity.
Yang G; Li L
J Chin Med Assoc; 2003 Apr; 66(4):210-6. PubMed ID: 12854872
[TBL] [Abstract][Full Text] [Related]
16. [The effect of milrinone administrated before weaning from cardiopulmonary bypass in adult cardiac surgery].
Hibino N; Tomino T; Satoh H; Hamawaki M; Imura M; Suzuki T; Inukai M
Kyobu Geka; 2000 Nov; 53(12):1019-23. PubMed ID: 11079307
[TBL] [Abstract][Full Text] [Related]
17. Neuronal nitric oxide synthase supports Renin release during sodium restriction through inhibition of phosphodiesterase 3.
Sällström J; Jensen BL; Skøtt O; Gao X; Persson AE
Am J Hypertens; 2010 Nov; 23(11):1241-6. PubMed ID: 20651700
[TBL] [Abstract][Full Text] [Related]
18. [How to use PDE III inhibitors].
Goto Y
Nihon Rinsho; 2007 May; 65 Suppl 5():49-56. PubMed ID: 17571365
[No Abstract] [Full Text] [Related]
19. [Phosphodiesterase III inhibitor--characteristics, mechanisms of action, pharmacokinetics, indications, contraindications, clinical trials, and side effects].
Sato N
Nihon Rinsho; 2007 May; 65 Suppl 5():43-8. PubMed ID: 17571364
[No Abstract] [Full Text] [Related]
20. Cyclic GMP and cyclic AMP induced changes in control and hypertrophic cardiac myocyte function interact through cyclic GMP affected cyclic-AMP phosphodiesterases.
Weiss HR; Gong GX; Straznicka M; Yan L; Tse J; Scholz PM
Can J Physiol Pharmacol; 1999 Jun; 77(6):422-31. PubMed ID: 10537228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
